Tim F Greten, M.D.
National Cancer Institute (NCI) · Department of Gastroenterology, Medizinische Hochschule Hannover
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
23
all conditions, ClinicalTrials.gov
NIH grants tied to them
1
NIH RePORTER
Trial papers
0
PubMed author-name match
Trials
Studies that name Tim F Greten, M.D. as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:05 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06603818 · Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)National Cancer Institute (NCI) · withdrawn · Microsatellite Stable Metastatic Colorectal Cancer, Metastatic Colorectal Cancer, Colorectal Cancer · principal investigator
- Ph1/Ph2NCT05849480 · A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)National Cancer Institute (NCI) · recruiting · Biliary Cancer, Bile Duct Cancer, Cancer of the Bile Duct · principal investigator
- Ph1NCT05003895 · GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor MalignanciesNational Cancer Institute (NCI) · recruiting · Hepatocellular Carcinoma, Hepatocellular Cancer, Metastatic Hepatocellular Carcinoma · principal investigator
- Ph2NCT04566133 · Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).National Cancer Institute (NCI) · terminated · Bile Duct Cancer, Biliary Cancer, Biliary Tract Neoplasms · principal investigator
- Ph2NCT04166383 · VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)National Cancer Institute (NCI) · terminated · Metastatic Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma · principal investigator
- N/ANCT04145141 · National Translational Science Network of Precision-based Immunotherapy for Primary Liver CancerNational Cancer Institute (NCI) · completed · Hepatocellular Carcinoma, Liver Cancer, Cholangiocarcinoma · principal investigator
- Ph2NCT04025567 · Vancomycin in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC) OralNational Cancer Institute (NCI) · withdrawn · Metastatic Hepatocellular Carcinoma, Hepatocellular Carcinoma · principal investigator
- Ph2NCT03937830 · Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract CarcinomaNational Cancer Institute (NCI) · active not recruiting · Hepatocellular Cancer, Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma · principal investigator
- Ph2NCT03785210 · Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic CancersNational Cancer Institute (NCI) · terminated · Hepatocellular Carcinoma, Hepatocellular Cancer, Metastatic Pancreatic Cancer · principal investigator
- N/ANCT03748927 · Natural History Study of Children and Adults With Fibrolamellar Hepatocellular CarcinomaNational Cancer Institute (NCI) · withdrawn · Hepatocellular Carcinoma, Hepatocellular Cancer · principal investigator
- Ph1/Ph2NCT03206073 · A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal CancerNational Cancer Institute (NCI) · completed · Colorectal Cancer, Colorectal Carcinoma, Colorectal Adenocarcinoma · principal investigator
- Ph2NCT03111732 · Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)National Cancer Institute (NCI) · completed · Biliary Tract Neoplasms, Cholangiocarcinoma, Bile Duct Cancer · principal investigator
- Ph2NCT02821754 · A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)National Cancer Institute (NCI) · completed · Biliary Tract Neoplasms, Liver Cancer, Hepatocellular Carcinoma · principal investigator
- N/ANCT02599909 · Gut Microbiota in People With Hepatocellular Carcinoma (HCC)National Cancer Institute (NCI) · withdrawn · Hepatocellular Carcinoma, Liver Cancer, Liver Cell Caricinoma · principal investigator
- Ph2NCT02417753 · AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant AscitesNational Cancer Institute (NCI) · terminated · Ovarian Cancer, Ovarian Neoplasms, Ascites · principal investigator
- Ph1/Ph2NCT02311361 · Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic CancerNational Cancer Institute (NCI) · completed · Pancreatic Neoplasms, Pancreatic Cancer, Cancer of Pancreas · principal investigator
- Ph1NCT02298946 · AMP-224, a PD-1 Inhibitor, With Stereotactic Body Radiation Therapy in Metastatic Colorectal CancerNational Cancer Institute (NCI) · completed · Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma · principal investigator
- Ph1/Ph2NCT01853618 · Tremelimumab With Chemoembolization or Ablation for Liver CancerNational Cancer Institute (NCI) · completed · Heptocellular Cancer, Biliary Tract Neoplasms, Liver Cancer · principal investigator
- Ph1/Ph2NCT01675128 · ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal CancerNational Cancer Institute (NCI) · completed · Colorectal Neoplasms, Colorectal Carcinoma, Colorectal Tumors · principal investigator
- Ph2NCT01375569 · TRC105 for Liver Cancer That Has Not Responded to SorafenibNational Cancer Institute (NCI) · completed · Hepatocellular Carcinoma, Hepatocellular Cancer, Carcinoma, Hepatocellular · principal investigator
- N/ANCT01313442 · Acquisition of Blood and Tumor Tissue Samples From Patients With Gastrointestinal CancerNational Cancer Institute (NCI) · recruiting · Non-GI Cancers, Cancer of Gastrointestinal Tract, Gastrointestinal Cancer · principal investigator
- Ph1/Ph2NCT01306058 · Sorafenib and TRC105 in Hepatocellular CancerNational Cancer Institute (NCI) · completed · Hepatoma, Liver Neoplasms, Adenoma, Liver Cell · principal investigator
- Ph3NCT00396682 · Elimination of CD4+CD25+ Regulatory T Cells in Patients With Hepatocellular CarcinomaHannover Medical School · completed · Advanced HCC · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:05 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- WISCONSIN HEART DISEASE AND STROKE PREVENTION PROGRAM WILL UTILIZE THE RESOURCES U58DP003962 · NCCDPHP · WISCONSIN DEPARTMENT OF HEALTH SERVICES · fiscal years 2014 · $350,000 awarded in 2014Same name and institution; not confirmed by an ID
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.